Navigation Links
Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
Date:5/18/2009

tegy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .



                         Simcere Pharmaceutical Group
            UNAUDITED CONSOLIDATED CONDENSED STATEMENTS OF INCOME
         (Amounts expressed IN THOUSANDS, EXCEPT SHARE AND ADS DATA)

                                             Three months ended March 31,
                                            2008          2009          2009
                                             RMB           RMB           USD

    Product revenue                      392,928       436,633        63,902
    Other revenue                          1,714         5,873           859
    Total revenue                        394,642       442,506        64,761

    Cost of materials and production     (66,120)      (77,320)      (11,316)
    Gross profit                         328,522       365,186        53,445

    Operating expenses:
    Research and development expenses    (17,773)      (25,047)       (3,666)
    Sales, marketing and distribution
     expenses                           (164,518)     (219,779)      (32,165)
    General and administrative
     expenses                            (47,027)      (59,288)       (8,677)
    Income from operations                99,204        61,072   
'/>"/>
SOURCE  Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 

Related biology technology :

1. Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009
2. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
3. Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009
4. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
5. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
6. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
7. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
8. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
9. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
10. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
11. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Vital Imaging ™ has teamed ... San Diego for a joint study which aims to ... Resonance Imaging) with that of a supine Dynawell MRI ... of improved healthcare by combining cutting edge technology with ... valuable tool for evaluating pathological changes in the spine, ...
(Date:5/21/2013)... 21, 2013 PathoGenetix, Inc., a commercial-stage ... typing, announced today that it has successfully identified and ... strains obtained from the Centers for Disease Control and ... technology. The findings are detailed in a poster ... Society for Microbiology in Denver on Monday. , The ...
(Date:5/20/2013)... , Collaboration with the ... in treatment of mastitis , ... to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate ... Service (ARS) to develop and trial products targeting the ...
(Date:5/20/2013)... 2013  MiMedx Group, Inc. (NASDAQ: MDXG ... protected regenerative biomaterials and bioimplants processed from human amniotic ... line of credit with Bank of America.  The revolving ... Company,s accounts receivable and inventory, allows MiMedx to borrow ... facility will be used for general corporate purposes. ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... now have a new tool to help diagnose symptomatic patients ... the most common sexually transmitted infections in the world.   ... and Company), announced today that it received U.S. Food and ... molecular tests to detect and differentiate HSV types 1 and ...
... BioTechnologies, Inc. (TriLink) announced that it has entered into ... its CleanAmp™ Products. The Scandinavian based TATAA develops and ... in addition to providing tailor-made products for real-time PCR ... Hot Start PCR, TriLink,s CleanAmp™ Product Line is an ...
... Inc. (OTC Bulletin Board: BONU ), a ... of Dr. Stephen Holt, M.D., Ph.D, a Distinguished Professor ... York State, as the Company,s Vice Chairman of the ... consultant to the pharmaceutical and dietary supplement industry, and ...
Cached Biology Technology:BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens 2TriLink Enters Into Distribution Agreement With TATAA Biocenter 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 3
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... 2013) The AGA Research Foundation announced a new ... between the gut microbiota, one of today,s most exciting ... , The AGA Research Awards Panel selected Andrew T. ... Hospital and Harvard Medical School, Boston, as the 2013 ... will receive $25,000 of funding, commencing in July 2013, ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... with the hepatitis C virus (HCV) are at an ... lymphatic system), according to a study published in the ... American Medical Association. Researchers from the National Cancer ... and Baylor College of Medicine, found that HCV infection ...
... greatest importance nowadays since it express who we are, but is ... its form? The answer to that question seems to be related ... Universidad Nacional Autonoma de Mexico and the Buck Institute in the ... than fashion. , In biology, the capacity to establish the ...
... Jake Najman and Gail Williams and Stockholm University's Professor Robin ... between 1981 and 2002. , Their results were published ... and Alcohol Review. , The men were categorised ... worker status is a marker for lower socio-economic status (SES). ...
Cached Biology News:Risk of lymphoma increases with hepatitis C virus infection 2Double the death rate from cirrhosis for 'blue collar' men 2
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... recombinant IFNA2. Immunogen: Human IFNA2 ... in E. coli. The biological activity was ... OMIM: 147562, GeneID: ... MA Code: ABV0P9DPB ...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Biology Products: